Won't be 'same ole, same ole' for ODAC at Perjeta meeting

23:20 EDT 8 Aug 2013 | SCRIP

The FDA said the guidance document was intended to encourage industry innovation and expedite the development of new therapies to treat high-risk early-stage breast cancer, a disease for which there remains a significant unmet medical need in certain...

Original Article: Won't be 'same ole, same ole' for ODAC at Perjeta meeting

NEXT ARTICLE

More From BioPortfolio on "Won't be 'same ole, same ole' for ODAC at Perjeta meeting"

Search BioPortfolio:
Loading
Advertisement

Relevant Topic

Breast Cancer
Latest News Clinical Trials Research Drugs Reports Corporate
Track and monitor developments in breast cancer research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on breast cancer and follow companies active in the development of breast cancer tr...

Advertisement